Development and application of hepatocellular carcinoma risk prediction model based on clinical characteristics and liver related indexes

Figure 1 Forest plot of variables in the diagnosis of hepatocellular carcinoma. OR: Odd ratio; CI: Confidence interval; HBsAg: Hepatitis B surface antigen; TBA: Total bile acid; TBIL: Total bilirubin; GGT: Gamma-glutamyl transferase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; AFP: Alpha-fetoprotein; PIVKA-II: Protein induced by vitamin K absence or antagonist-II.

Figure 2 Nomogram to predict the presence of hepatocellular carcinoma. HBsAg: Hepatitis B surface antigen; TBA: Total bile acid; TBIL: Total bilirubin; GGT: Gamma-glutamyl transferase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; AFP: Alpha-fetoprotein; PIVKA-II: Protein induced by vitamin K absence or antagonist-II; HCC: Hepatocellular carcinoma.

Figure 3 Diagnostic values of NSMC-hepatocellular carcinoma model, vitamin K absence or antagonist-II and alpha-fetoprotein in hepatocellular carcinoma patients and early-stage hepatocellular carcinoma patients. A and B: Comparison of the area under the receiver operating characteristic curve between NSMC-hepatocellular carcinoma (HCC) model and alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonist-II (PIVKA-II) alone or both for HCC diagnosis in training cohort (A) and validation cohort (B); C and D: Compare the area under the operating characteristic curve of subjects using NSMC-HCC model and AFP, PIVKA-II alone or both for HCC diagnosis in the early-stage HCC in training cohort (C) and validation cohort (D). CI: Confidence interval; AFP: Alpha-fetoprotein; PIVKA-II: Protein induced by vitamin K absence or antagonist-II; HCC: Hepatocellular carcinoma; AUC: Area under receiver operating characteristic curve.